Human telomerase reverse transcriptase expression in ovarian tumors

Indian Journal of Pathology and Microbiology

Volumn 55, Issue 2, 2012, Pages 187-191

  Maraei, Awadh Ali ^a   Hatta, Ahmad ^a   Shiran, Mohd ^b   Tan, Geok ^a  

^a UNIVERSITI KEBANGSAAN MALAYSIA   (Malaysia)

^b UNIVERSITY PUTRA MALAYSIA   (Malaysia)

Author keywords

Borderline ovarian tumor; CA 125; hTERT; immunohistochemistry; ovary

Indexed keywords

CA 125 ANTIGEN; TELOMERASE REVERSE TRANSCRIPTASE;

ARTICLE; CANCER GRADING; CANCER STAGING; CYSTADENOCARCINOMA; FEMALE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; OVARIAN EPITHELIAL TUMOR; OVARY TUMOR; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION;

ADULT; AGED; AGED, 80 AND OVER; CA-125 ANTIGEN; FEMALE; GENE EXPRESSION; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; TELOMERASE; TUMOR MARKERS, BIOLOGICAL;

EID: 84863760884     PISSN: 03774929     EISSN: 09745130     Source Type: Journal    
DOI: 10.4103/0377-4929.97865     Document Type: Article

References (28)

1. Lim GC, Halimah Y, editors. Second Report of the National Cancer Registry. Cancer Incidence in Malaysia 2003. National Cancer Registry. Kuala Lumpur, 2004.
2. Gayther SA, Pharoah PD. The inherited genetics of ovarian and endometrial cancer. Curr Opin Genet Dev 2010;20:231-8.
3. Auersperg N, Wong AS, Choi KC, Kang SK, Leung PC. Ovarian surface epithelium: Biology, endocrinology, and pathology. Endocr Rev 2001;22:255-88.
4. Siriaunkgul S, Robbins KM, McGowan L, Silverberg SG. Ovarian mucinous tumors of low malignant potential: A clinicopathologic study of 54 tumors of intestinal and mullerian type. Int J Gynecol Pathol 1995;14:198-208.
5. Pickel H, Tamussino K. History of gynecological pathology. XIV. Hermann Joannes Pfannenstiel. Int J Gynecol Pathol 2003;22:310-4.
6. Hart WR. Borderline epithelial tumors of the ovary. Modern Pathol 2005;18:S33-50.
7. Hart WR, Norris HJ. Borderline and malignant mucinous tumors of the ovary. Histologic criteria and clinical behavior. Cancer 1973;31:1031-45.
8. Juan R. Female Reproductive System, Ovary. In. Rosai and Ackreman's Surgical Pathology. 9th ed. Vol. 2. Philadelphia: Mosby; 2004. p. 1659-66.
9. Serov SF, Scully RE, Sobin LH. International Histologic Classification of Tumours. Histological Typing of Ovarian Tumours. Geneva: World Health Organization; 1973.
10. Tavassoli FA, Devilee P, editors. World Health Organization Classification of Tumours. Pathology and Genetics. Tumours of the Breast and Female Genital Organs. Lyon: IARC Press; 2003.
11. Yin BW, Dnistrian A, Lloyd KO. Ovarian cancer antigen CA125 is encoded by the MUC16 mucin gene. Int J Cancer 2002;98:737-40.
12. Duraisamy S, Ramasamy S, Kharbanda S, Kufe D. "Distinct evolution of the human carcinoma-associated transmembrane mucins, MUC1, MUC4 AND MUC16". Gene 2006;373:28-34.
13. Bast RC, Feeney M, Lazarus H, Nadler LM, Colvin RB, Knapp RC. "Reactivity of a monoclonal antibody with human ovarian carcinoma". J Clin Invest 1981;68:1331-7.
14. Bonnar J, Dunlop W. Overview of ovarian cancer screening. In. Recent Advances in Obstetrics and Gynaecology. Vol. 23. London: RSM Press; 2005. p. 246.
15. Feng J, Funk WD, Wang SS, Weinrich SL, Avilion AA, Chiu CP, et al. The RNA component of human telomerase. Science 1995;269:1236-41.
16. Nakamura TM, Morin GB, Chapman KB, Weinrich SL, Andrews WH, Lingner J, et al. Telomerase catalytic subunit homologs from fission yeast and human. Science 1997;277:955-9.
17. Meyerson M, Counter CM, Eaton EN, Ellisen LW, Steiner P, Caddie SD, et al. hEST2, the putative human telomerase catalytic subunit gene, is up-regulated in tumor cells and during immortalization. Cell 1997;90:785-95.
18. Harrington L, McPhail T, Mar V, Zhou W, Oulton R, Bass MB, et al. A mammalian telomerase-associated protein. Science 1997;275:973-7.
19. Holt SE, Aisner DL, Baur J, Tesmer VM, Dy M, Ouellette M, et al. Functional requirement of p23 and Hsp90 in telomerase complexes. Genes Dev 1999;3:817-26.
20. Liu J, Yang G, Thompson-Lanza JA, Glassman A, Hayes K, Patterson A, et al. A genetically defined model for human ovarian cancer. Cancer Res 2004;64:1655-63.
21. Demetri GD, von Mehren M, Blanke CD, Van den Abbeele AD, Eisenberg B, Roberts PJ, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002;347:472-80.
22. Shimizu Y, Kamoi S, Amada S, Akiyama F, Silverberg SG. Toward the development of a universal grading system for ovarian epithelial carcinoma: Testing of a proposed system in a series of 461 patients with uniform treatment and follow-up. Cancer 1998;82:893-901.
23. Sood AK, Coffin J, Jabbari S, Buller RE, Hendrix MJ, Klingelhutz A. p53 null mutations are associated with a telomerase negative phenotype in ovarian carcinoma. Cancer Biol Ther 2002;1:511-7.
24. Kyo S, Masutomi K, Maida Y, Kanaya T, Yatabe N, Nakamura M, et al. Significance of immunological detection of human telomerase reverse transcriptase: Re-evaluation of expression and localization of human telomerase reverse transcriptase. Am J Pathol 2003;163:859-67.
25. Tantbirojn P, Triratanachat S, Trivijitsilp P, Niruthisard S. Human telomerase reverse transcriptase (hTERT) expression in borderline ovarian tumors: An immunohistochemical study. J Med Assoc Thai 2009;92:308-14.
26. Brustmann H. Immunohistochemical detection of human telomerase reverse transcriptase (hTERT) and c-kit in serous ovarian carcinoma: A clinicopathologic study. Gynecol Oncol 2005;98:396-402.
27. Kyo S, Kanaya T, Takakura M, Tanaka M, Yamashita A, Inoue H, et al. Expression of human telomerase subunits in ovarian malignant, borderline and benign tumors. Int J Cancer 1999;80:804-9.
28. Wisman GB, Hollema H, Helder MN, Knol AJ, Van der Meer GT, Krans M, et al. Telomerase in relation to expression of p53, c-Myc and estrogen receptor in ovarian tumours. Int J Oncol 2003;23:1451-9.